Patents Examined by Shawquia Jackson
  • Patent number: 12043594
    Abstract: The present disclosure provides a novel biphenyl derivative compound, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The biphenyl derivative compound, optical isomer thereof or pharmaceutically acceptable salt thereof according to the present disclosure may induce cancer cell death by damaging mitochondria and inducing ATP depletion in cells which are in a nutrient-starved state such as a glucose-starved state, which is the normal environment of cancer cells. In addition, it is an Nm23-H1/NDPK activity-increasing substance that may suppress cancer metastasis and growth. Thus, it exhibits excellent effects not only on the prevention, alleviation and treatment of cancer, but also on the suppression of cancer metastasis.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: July 23, 2024
    Assignee: EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
    Inventors: Kong Joo Lee, Hee-Yoon Lee, Je Jin Lee, Hongsoo Lee, Ji-wan Seo, Hwang Suk Kim, Bo-kyung Kim, Ji Soo Shin
  • Patent number: 12043602
    Abstract: The invention relates generally to the following novel fendiline derivatives, and the preparation and use thereof: Formula I (I) and Formula II (II)
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: July 23, 2024
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: John F. Hancock, Jia Zhou, Dharini van der Hoeven, Jeffrey A. Frost, Na Ye, Pingyuan Wang
  • Patent number: 12035616
    Abstract: Provided is an organic electroluminescence device. The organic electroluminescence device according to an embodiment includes a first electrode, a second electrode facing the first electrode, and a plurality of organic layers between the first electrode and the second electrode, wherein at least one of the plurality of organic layers includes an organometallic complex including a metal atom which is a central atom, a plurality of ligand connected to the metal atom, and a nitrogen atom connecting two of the plurality of ligands. The nitrogen atom includes an aromatic ring group as a substituent. The aromatic ring group is not bonded to any of the plurality of ligands to form a ring, thereby allowing the organic electroluminescent device to exhibit a low drive voltage and improved life time.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: July 9, 2024
    Assignee: Samsung Display Co., Ltd.
    Inventors: Haejin Kim, Soo-Byung Ko, Sungbum Kim, Sujin Shin, Eunsoo Ahn, Eunyoung Lee, Jaesung Lee, Hyunjung Lee, Mina Jeon, Junghoon Han
  • Patent number: 12018002
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: June 25, 2024
    Assignee: NEUPHARMA, INC
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Patent number: 12018018
    Abstract: Provided are a pregabalin lactam methylene dimer and a preparation method therefor. The method comprises the following steps: dissolving pregabalin in a reaction solvent, reacting same with an aldehyde in an acidic system and isolating the obtained target product pregabalin lactam methylene dimer. The preparation method for pregabalin lactam methylene dimer provided by the present application has a simple operation, a high product yield, a good purity and a low cost.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 25, 2024
    Assignees: Zhejiang Huahai Pharmaceutical Co., Ltd, Zhejiang Huahai Zhicheng Pharmaceutical Co., Ltd.
    Inventors: Jinsheng Lin, Xiaofei Liu, Dan Li, Jing Wang, Yue Li, Wenquan Zhu, Wenbin Chen, Min Li
  • Patent number: 12012411
    Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: June 18, 2024
    Assignee: Katholieke Universiteit Leuven
    Inventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
  • Patent number: 12006298
    Abstract: The present invention provides freebase and salt forms, and compositions and methods thereof, useful for treating various conditions in which aldehyde toxicity is implicated in the pathogenesis by the administration of small molecule therapeutics acting as a scavenger for toxic aldehydes.
    Type: Grant
    Filed: August 6, 2019
    Date of Patent: June 11, 2024
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Stephen Gitu Machatha, Jonathan J. Loughrey, Hannah Ruth Mclachlan, Gregor Sneddon
  • Patent number: 11999723
    Abstract: In one aspect, the invention comprises compounds that bind and inhibit macrophage migration inhibitory factor. In another aspect, the invention provides methods of treating, ameliorating, and/or preventing inflammatory disease, neurological disorders and cancer using the compounds of the invention.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: June 4, 2024
    Assignee: YALE UNIVERSITY
    Inventors: William L. Jorgensen, Vinay Trivedi-Parmar
  • Patent number: 11999693
    Abstract: Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: June 4, 2024
    Assignee: The Regents of the University of California
    Inventors: Aimee L. Edinger, Stephen Hanessian
  • Patent number: 11988667
    Abstract: Provided are any one of the following fluorescent compounds and a fluorescent labeled biological substance having this fluorescent compound. X represents CR5 or N, and R1 to R7, Q1, Q2, L1, and L2 each represent a specific group. a ring ?1 and a ring ?2 are a 5- to 8-membered ring, At least one of R1 to R7, L1, L2, Q1, or Q2 has a specific hydrophilic group. However, in a case where the ring ?1 and the ring ?2 are a 6-membered ring, and L1 and L2 are an arylene group, R5 is not an aryl group substituted with a linear alkyl group having 18 or more carbon atoms. In addition to the regulation of the ring ?1, the ring ?2, L1, and L2, in a case where R5 has a substituent having a dipyrromethene boron complex structure, the dipyrromethene boron complex structure has a structure in which a dipyrromethene skeleton is coordinately bonded to a boron atom in the tridentate or tetradentate coordination.
    Type: Grant
    Filed: November 27, 2020
    Date of Patent: May 21, 2024
    Assignee: FUJIFILM Corporation
    Inventors: Hiyoku Nakata, Kousuke Watanabe, Akihiro Asakura, Keiko Makita, Yoshinori Kanazawa, Kazuhei Kaneko
  • Patent number: 11987582
    Abstract: Pharmaceutical compositions and methods of using maleate salts of triazolopyrazine derivatives are provided. In some aspects, the pharmaceutical compositions have improved storage stability and pharmacokinetic properties. The maleate salts of triazolopyrazine derivatives bind competitively to the phosphorylation site of c-MET kinase and can be used for the treatment or prevention of various hyper proliferative disorders.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: May 21, 2024
    Assignee: ABION Inc.
    Inventors: Jun Young Choi, Kyung Eui Park, Yeong Mun Kim
  • Patent number: 11987555
    Abstract: The present invention relates to compounds, compositions, and methods for brightening skin. The compounds, compositions, and methods of the present invention generally involve compounds produced by a Malassezia yeast, and chemical analogs thereof. In addition to skin brightening applications, the compounds, compositions, and methods of the present invention may be used to modulate melanocyte activity, induce melanocyte apoptosis, agonize an arylhydrocarbon receptor (AhR), improve hyperpigmentation caused by a hyperpigmentation disorder, and modulate melanin production, melanosome biogenesis, and melanosome transfer.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: May 21, 2024
    Assignee: VERSICOLOR TECHNOLOGIES, LLC
    Inventors: Michael Einziger, Ann Marie Simpson
  • Patent number: 11987709
    Abstract: Disclosed herein, inter alia, are silicon containing detectable compounds and methods of use thereof. In an aspect is provided a monovalent nucleotide or monovalent nucleoside covalently bound to a monovalent form of a compound described herein (e.g., wherein the R13 moiety of a compound described herein has reacted with a bioconjugate reactive group to form a bioconjugate linker thereby covalently bonding the monovalent compound to the monovalent nucleotide or monovalent nucleoside).
    Type: Grant
    Filed: August 5, 2022
    Date of Patent: May 21, 2024
    Assignee: Singular Genomics Systems, Inc.
    Inventors: Megha Cila, Ronald Graham, Rodrigo Rodriguez
  • Patent number: 11981680
    Abstract: The present invention provides compounds of formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: May 14, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: Daniel S. Gardner, John V. Duncia, Joseph B. Santella
  • Patent number: 11981642
    Abstract: A 4-(4,5-bis(4-bromophenyl)-2-(4-chlorophenyl)-1H-imidazol-1-yl)butanoic acid compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 26, 2023
    Date of Patent: May 14, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11976059
    Abstract: The present invention relates to an isoindolin-1-on derivative, a method for preparing same, and a pharmaceutical composition comprising same as an effective component for preventing or treating tumors, wherein the isoindolin-1-on derivative exhibits a high inhibitory effect on EGFR mutations, and thus can be beneficially used for the treatment of EGFR-mutated tumors, and the isoindolin-1-on derivative exhibits a significant synergistic effect when co-administered, and thus can be beneficially used in concomitant therapy.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: May 7, 2024
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Kwangho Lee, Gildon Choi, Seoyoung Lee, Jiwon Kim, Byoung Chul Cho, Chae Won Park, Jiyeon Yun
  • Patent number: 11976052
    Abstract: Provided are specific leukotriene synthesis inhibitor compounds and pharmaceutical compositions comprising the compounds and methods of using the compounds and the pharmaceutical compositions in treating, for example, inflammatory diseases or conditions.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: May 7, 2024
    Assignee: Naegis Pharmaceuticals Inc.
    Inventors: David L. Burgoyne, Erin DeBruin, Julia Fonarev, James Gee Ken Yee, John Michael Langlands
  • Patent number: 11975005
    Abstract: The present invention relates to compositions, methods and kits for the treatment of respiratory disease. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment or prevention of exacerbations of asthma and chronic obstructive pulmonary disease. The present invention provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of casein kinase 1, thereby treating or preventing a respiratory disease in a subject. The present invention also provides a method of treating or preventing a respiratory disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an inhibitor of ALK5, thereby treating or preventing a respiratory disease in a subject, wherein the inhibitor is administered directly to the airway and/or lungs.
    Type: Grant
    Filed: December 22, 2022
    Date of Patent: May 7, 2024
    Assignee: TIANLI BIOTECH PTY LTD
    Inventors: Alastair Stewart, Christine Keenan, Trudi Harris
  • Patent number: 11970446
    Abstract: The present invention relates to novel crystalline salt forms of mesembrine, also known as 3a-(3,4-dimethoxyphenyl)-octahydro-1-methy-6H-indol-6-one. Mesembrine has the chemical formula C17H23NO3. The invention further relates to the preparation of a novel crystalline salt of mesembrine and to the use of the mesembrine salt as a medicament. In one embodiment the novel crystalline salt form of mesembrine is mesembrine besylate salt.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: April 30, 2024
    Assignee: Kanna Health LTD
    Inventor: Ryan Joseph Protzko
  • Patent number: 11970457
    Abstract: The present invention relates to metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine. These metabolites may act as RAGE antagonists. These metabolites may also be useful in assays to measure the presence or amount of one or more metabolites of the parent compound in a sample.
    Type: Grant
    Filed: October 27, 2022
    Date of Patent: April 30, 2024
    Assignee: VTV THERAPEUTICS LLC
    Inventors: William Kenneth Banner, Bapu Gaddam, Dharma Rao Polisetti, Robert Carl Andrews, Samuel Victory